Biotech Values

[biomaven0]

>>the DNDN'ites over at IV will mock the 2.2 MOS number

The key difference is that aside from OS there were a number of very favorable secondary outcomes:

The median times to deterioration in a measure of prostate cancer-specific quality of life, the Functional Assessment of Cancer Therapy-Prostate or FACT-P, were 11.3 months for the enzalutamide-treated patients and 5.6 months for the placebo patients (HR=0.625, p < 0.0001).

And an 18 month delay in starting chemo is pretty dramatic too.

The other notable disclosure was the incidence of seizures - one in the drug arm and one in the placebo arm, both with pre-existing seizure conditions. So really this seems to be a non-issue.

Peter